Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

BACKGROUND A well-recognized class effect of immune checkpoint inhibitors(ICI)is immune-related adverse events(IrAEs)ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI.Deaths are reported in<5%of patients treated with ICI.There are,however,no reliable markers to predict the onset and severity of IrAEs.We tested the association between neutrophil-lymphocyte ratio(NLR)and platelet-lymphocyte ratio(PLR)at baseline with development of clinically significant IrAEs(grade≥2)in hepatocellular carcinoma(HCC)patients treated with ICI.AIM To test the association between NLR and PLR at baseline with development of clinically significant IrAEs(grade≥2)in HCC patients treated with ICI.METHODS Data was extracted from an international database from a consortium of 11 tertiary-care referral centers.NLR=absolute neutrophil count/absolute lymphocyte count(ALC)and PLR=platelet count/ALC.Cutoff of 5 was used for NLR and 300 for PLR based on literature.We also tested the association between RESULTS Data was collected from 361 patients treated between 2016-2020 across the United States(67%),Asia(14%)and Europe(19%).Most patients received Nivolumab(n=255,71%).One hundred sixty-seven(46%)patients developed at least one IrAE,highest grade 1 in 80(48%),grade≥2 in 87(52%)patients.In a univariable regression model PLR>300 was significantly associated with a lower incidence of grade≥2 IrAEs(OR=0.40;P=0.044).Similarly,a trend was observed between NLR>5 and lower incidence of grade≥2 IrAEs(OR=0.58;P=0.097).Multivariate analyses confirmed PLR>300 as an independent predictive marker of grade≥2 IrAEs(OR=0.26;P=0.011),in addition to treatment with programmed cell death ligand 1(PD-1)/cytotoxic T lymphocyte-associated protein-4(OR=2.57;P=0.037)and PD-1/tyrosine kinase inhibitor(OR=3.39;P=0.01)combinations.Antibiotic use was not associated with IrAE incidence(OR=1.02;P=0.954).Patients treated with steroids had a>2-fold higher incidence of grade≥2 IrAEs(OR=2.74;P<0.001),although 74%were prescribed steroids for the treatment of IrAEs.CONCLUSION Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs,lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI.This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs.

Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer

AIMTo identify simple and sensitive markers for postoperative complications after gastrectomy, the predictive values were compared among candidate preoperative factors.METHODSThree-hundred and twelve patients with previously untreated clinical T2-4 gastric cancer who underwent a D2 standard gastrectomy (distal gastrectomy or total gastrectomy) were included in the analysis. Correlations between 21 parameters that can be determined by preoperative routine blood tests and clinically relevant postoperative complications (grade II or higher according to the Clavien-Dindo classification) were evaluated. The optimal cutoff values and clinical significance of the selected markers were further evaluated by subgroup analyses according to age, body mass index, operative procedure and clinical disease stage.RESULTSSixty-six patients (21.1%) experienced grade II or higher postoperative complications. The platelet-lymphocyte ratio (PLR, total lymphocyte count/platelet count × 100) exhibited the highest area under the curve value (0.639) for predicting postoperative complications among the 21 parameters, and the optimal cutoff value was determined to be 0.71 (sensitivity = 70%, specificity = 56%). In the univariate analysis, the odds ratio of a low PLR for the occurrence of postoperative complications was 2.94 (95%CI: 1.66-5.35, P < 0.001), and a multivariate binomial logistic analysis involving other potential risk factors identified a low PLR as an independent risk factor for postoperative complications (OR = 3.32, 95%CI: 1.82-6.25, P < 0.001). In subgroups classified according to age, body mass index, operative procedure and clinical disease stage, the low PLR group exhibited an increased incidence of postoperative complications.CONCLUSIONThe preoperative PLR is a simple and useful predictor of complications after curative gastrectomy in patients with clinical T2-4 gastric cancer.

The Prognostic Significance of the Preoperative Platelet-Lymphocyte Ratio in Japanese Patients with Localized Breast Cancer

Inflammation has been shown to be a factor in tumorigenesis. The circulating platelet to lymphocyte ratio (PLR) is a representative index of systemic inflammation. In this study, we analyzed the association between preoperative PLR levels and clinicopathological variables in two hundred sixty-four Japanese patients with localized breast carcinoma. We also evaluated the prognostic significance of preoperative PLR levels using the Cox proportional hazard model. Seventy-five patients (28.4%) had elevated PLR values, whereas 189 (71.6%) had depressed PLR values. The PLR correlated significantly with venous invasion (P < 0.05). Disease-free survival rates were significantly worse among patients with elevated PLR values than among those with lower PLR value (5-year survival, 81.6% vs. 90.7%, respectively;P < 0.05). In multivariate analysis, elevated PLR, nuclear grade, and lymph node involvement were significant prognostic factors for disease-free survival in patients with breast carcinoma (P < 0.05). Preoperative PLR levels may be an independent prognostic factor in patients with breast carcinoma.

Significances of Peripheral Inflammatory Cells and Neutrophil/Platelet-Lymphocyte Ratio in Breast Cancer after Resection

Introduction: Breast cancer had become top leading cause of death in Taiwan and endangered women’s health worldwide. Therefore, we try to invest the peripheral inflammatory cell counts and neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) from our routine practice for the predictor of prognosis of breast cancer after resection. Patients and Methods: There were 574 breast cancer patients accepted surgical resection and registered in Cancer Registry Center of our hospital. Patient’s basic profiles, peripheral neutophil, lymphocyte and platelet count were measured for study. The scales of NLR and PLR were derived from the lower and higher normal range in cell count from neutrophil, lymphocyte and platelet respectively. Therefore, the scales for NLR and PLR were ≤1.62, 1.63 - 2.57, ≥2.58 and ≤224, 225 - 253, ≥254 respectively for analysis. Results: Poor 5-yr survival rate was found if higher cell counts of neutrophil and platelet (p ≤ 0.05). Three scales of NLR were ≤1.62, 1.63 - 2.57, ≥2.58, and their 5-year survival rates were 94%, 91% and 84% respectively (p = 0.019). In the subgroup of HER-2 (negative), and 3-Negative breast patients had a higher NLR of poor prognosis. But higher PLR was found less in 3-Negative and non in 3-Positive patients (p = 0.039). The PLR was ≤224, 225 - 253, ≥254 and their 5-year survival rates were 92%, 87%, and 64% respectively (p = 0.001);Multivariate Cox regression model for predictor of breast cancer patients who have 3.39 (PLR ≥ 254) and 2.45 (NLR ≥ 2.58 ) times risk (p = 0.02 and p = 0.002) of poor prognosis respectively. Conclusion: Peripheral inflammatory cell counts are easily to take in our clinical practice and have a potential role as predictors of prognosis. We have to pay attention to the trends of peripheral inflammatory cell count and their ratio in our clinical practice where possible.

早期NLR、PLR、N/LP及其联合其他因素在预测重度创伤性颅脑损伤早期预后的研究

目的探讨人外周血早期中性粒细胞-淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)、血小板-淋巴细胞比值(platelet to lymphocyte ratio,PLR)和中性粒细胞-淋巴细胞和血小板比值(neutrophils to lymphocytes and platelets ratio,N/LP)在重度创伤性颅脑损伤(severe traumatic brain injury,sTBI)患者早期结果中的预测价值。方法回顾性分析2014年6月-2016年12月中国医科大学第七临床学院神经外科收治的95例sTBI患者的临床资料。比较预后良好组(n=36)和预后不良组(n=59)患者的早期NLR、PLR和N/LP差异,分析影响预后相关危险因素并绘制森林图,采用多因素logsitic回归确定独立危险因素并构建临床预测模型;绘制出受试者工作特征曲线(receiver operating characteristic curve,ROC),分析并比较NLR、PLR和N/LP单独或联合其他指标构建出的不同临床预测模型的差异。结果sTBI预后良好组和预后不良组早期NLR、PLR和N/LP比较,差异均有统计学意义(P<0.05);多因素logsitic回归分析提示,年龄、入院格拉斯哥昏迷评分(Glasgow coma scale,GCS)、NLR、PLR和N/LP是影响sTBI患者早期结果的独立危险因素,差异有统计学意义(P<0.05)。根据多因素logstic回归分析构建出19个临床预后预测模型,其中NLR+PLR+N/LP及其联合指标(年龄和GCS)模型曲线下面积(area under curve,AUC)均高于同组其他模型,分别为0.912、0.935、0.933和0.954;Age+GCS+NLR+PLR+N/LP预测模型在所有组别中AUC最大,表明该模型预测患者预后的价值最高。结论NLR、PLR和N/LP的升高与sTBI不良预后相关;早期NLR、PLR及N/LP联合年龄和GCS评分在sTBI早期结果预测中具有重要价值。

术前外周血SII、NLR、PLR对宫颈癌淋巴结转移的评估价值

目的探讨术前外周血系统免疫炎症指数(SII)、中性粒细胞与淋巴细胞比(NLR)、血小板与淋巴细胞比(PLR)与宫颈癌淋巴结转移的相关性,分析其预测价值。方法回顾性分析我院2016年1月至2020年1月收治的191例宫颈癌患者的临床资料,根据组织病理学淋巴结是否转移将其分为转移组(n=31)和未转移组(n=160)。采用单因素和多因素Logistic回归分析淋巴结转移的影响因素;通过受试者工作特征(ROC)曲线分析SII、NLR和PLR预测淋巴结转移的最佳界值和效能;分析SII、NLR和PLR与临床病理特征的关系。结果单因素分析显示,肿瘤≥4cm、脉管浸润、高SII、高NLR、高PLR的患者中淋巴结转移发生率较高(χ^(2)/Z值分别为4.532、8.342、14.363、4.837、11.478,P<0.05);多因素分析显示,肿瘤≥4cm(OR=2.347,95%CI:1.645~4.272)、脉管浸润(OR=1.924,95%CI:1.724~2.236)、高SII(OR=2.458,95%CI:1.557~1.968)、高PLR(OR=1.884,95%CI:1.418~8.654)是宫颈癌患者淋巴结转移的危险因素。ROC分析显示,SII、NLR和PLR预测宫颈癌淋巴结转移的界值分别为424.57、2.45和142.51,曲线下面积(AUC)分别为0.765、0.691、0.715,且三者联合的预测价值更高(AUC=0.836)。高SII组中高龄(≥50岁)、淋巴结转移、肿瘤≥4cm、ⅡA期、脉管浸润比例较高(P<0.05);高NLR和高PLR组中淋巴结转移、肿瘤≥4cm、脉管浸润比例较高(P<0.05)。结论SII、NLR和PLR是宫颈癌淋巴结转移的预测指标,三者联合的预测价值更高;高SII和高PLR是宫颈癌淋巴结转移的危险因素,具有一定的临床指导意义。

乙型流感患者外周血NLR、PLR和SII的水平及其临床意义

目的探讨中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)、全身免疫炎症指数(SII)在乙型流感患者外周血中的水平变化及临床意义。方法选取2020年1月在上海市浦东新区公利医院门急诊就诊的有流感样症状的154例患者为研究对象,根据乙型流感病毒抗原结果,分为阳性组74例和阴性组80例,另选取同期75例健康体检者为对照组。采集3组对象的静脉血检测血常规,计算NLR、PLR和SII;比较阳性组不同性别的血常规指标及NLR、PLR和SII的水平;采用受试者工作特征(ROC)曲线分析NLR、PLR和SII对乙型流感的预测价值。结果阳性组和阴性组NLR、PLR和SII水平显著高于对照组(H=88.48、58.61、42.16,均P<0.001)。乙型流感患者不同性别间的NLR、PLR和SII水平比较差异无统计学意义(P>0.05)。NLR,PLR和SII对乙型流感预测的ROC面积分别为0.917、0.847和0.793。NLR,PLR和SII的最佳临界值为2.46,134.41和600.45,其对应的灵敏度分别是89.2%、81.1%和68.9%;特异性分别是86.7%、84.0%和85.3%;准确度分别是87.9%、82.5%和77.2%。结论乙型流感患者外周血NLR、PLR和SII升高,NLR、PLR和SII可早期辅助诊断乙型流感。

PLR-PNI对TACE治疗中晚期肝癌生存期的预测分析

目的 探讨血小板/淋巴细胞比值(PLR)和预后营养指数(PNI)联合评分与肝癌患者经导管肝动脉化疗栓塞术(TACE)后生存期的关系。方法 回顾性分析十堰市太和医院95例接受TACE治疗的中晚期肝癌患者的临床和随访资料。计算并分析其PLR和PNI的联合评分对患者生存率的影响。采用Kaplan-Meier法进行生存分析,采用Cox比例风险模型分析患者术后生存期的危险因素。分析不同PLR-PNI联合评分患者术后生存期差异。结果 生存分析显示PLR-PNI联合评分0、1、2分患者的生存率分别为48.7%、26.0%和14.7%(P<0.05);多因素分析显示AFP水平、肿瘤直径、血管侵犯、BCLC分期,PLR-PNI评分是影响TACE术后患者生存期的独立危险因素。结论 患者PLR和PNI联合评分可用于评估肝癌患者经TACE治疗生存期,评分越低的患者生存率越高。

Prognostic value of platelet-to-lymphocyte ratio in upper tract urothelial carcinoma patients treated with radical nephroureterectomy:A metaanalysis

Objective:To evaluate the prognostic value of platelet-to-lymphocyte ratio(PLR)in upper tract urothelial carcinoma(UTUC)patients treated with radical nephroureterectomy.Methods:This study was pre-registered in PROSPERO(No.CRD42020186645).Two reviewers independently performed a comprehensive literature search on PubMed,Web of Science,EMBASE,Cochrane Library databases,China Biology Medicine disc(CBM),Wanfang database,and China National Knowledge Infrastructure(CNKI)from inception to May 2021 for prospective or retrospective cohort studies evaluating the prognostic value of PLR.Literature was analyzed with inclusion and exclusion criteria.Data and other useful clinicopathological features were extracted and analyzed with fixed or random-effect models when applicable.Heterogeneity was assessed on the basis of Cochran’s Q test and I2 statistic.Publication bias was assessed with funnel plots and precisely assessed by Egger's tests.Results:A total of ten studies involving 3287 UTUC patients were included.Meta-analysis showed that elevated preoperative PLR was associated with worse overall survival(HR=1.51,95%CI 1.17-1.94,P=0.001),cancer specific survival(HR=1.52,95%CI 1.21-1.90,P<0.001),disease free survival(HR=1.32,95%CI 1.12-1.56,P=0.001),and progression free survival(HR=1.88,95%CI 1.41-2.52,P<0.001).Furthermore,the sensitivity analyses validated the stability and reliability of the results.Conclusion:The present meta-analysis demonstrates a significant association between elevated preoperative PLR and poor prognosis of UTUC patients treated with radical nephroureterectomy.Hence,PLR could be helpful as a potential prognostic biomarker to guide clinical decision-making and select individualized treatment strategies for UTUC patients.However,more prospective and large-scale trials are needed to provide more evidence.

NHR联合PLR对老年退行性心脏瓣膜病患者瓣膜钙化的诊断价值

目的:探讨中性粒细胞/高密度脂蛋白胆固醇比值(NHR)联合血小板/淋巴细胞比值(PLR)对老年退行性心脏瓣膜病(SDHVD)患者瓣膜钙化的诊断价值。方法:选择2019年11月至2021年11月就诊于南通大学附属南通第三医院的229例心脏瓣膜钙化患者作为观察组,选取同期超声心动图结果正常的非心脏瓣膜钙化患者229例作为对照组。血常规分析仪及生化分析仪检测两组患者的指标,计算NHR、PLR,应用受试者工作特征曲线(ROC)评价NHR联合PLR在辅助诊断SDHVD瓣膜钙化中的价值。结果:观察组白细胞计数为6.21(5.25~7.99)×10^(9)/L,高于对照组的5.83(4.54~7.25)×10^(9)/L(P<0.05)。观察组中性粒细胞计数为4.25(3.19~5.54)×10^(9)/L,高于对照组3.52(2.70~4.79)×10^(9)/L(P<0.001)。观察组血小板计数为195.50(152.50~232.50)×10^(9)/L,高于对照组175.00(138.00~213.00)×10^(9)/L(P<0.05),对照组高密度脂蛋白胆固醇1.21(0.98~1.49)mmol/L高于观察组1.11(0.92~1.34)mmol/L(P<0.05)。NHR观察组3.74(2.55~5.69)高于对照组3.07(2.13~4.29)(P<0.001)。PLR观察组147.13(107.99~196.54)高于对照组125.00(97.88~161.21)(P<0.001)。ROC曲线结果显示,将4.56作为NHR阈值,曲线下面积为0.627,诊断SDHVD瓣膜钙化的敏感度和特异性分别为38.90%和81.70%;将138.98作为PLR阈值,曲线下面积为0.624,诊断SDHVD瓣膜钙化敏感度和特异性分别为57.60%和60.30%。联合NHR和PLR诊断SDHVD瓣膜钙化最佳截断值为280.66,曲线下面积为0.681,灵敏度和特异性分别为58.10%和65.10%。结论:SDHVD瓣膜钙化患者NHR和PLR均存在变化,NHR联合PLR可作为SDHVD瓣膜钙化辅助诊断的指标。

外周血NLR与PLR对原发性胃癌患者生存状况的评估价值

目的探讨原发性胃癌患者入院时中性粒细胞与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)和血小板与淋巴细胞比值(platelet-to-lymphocyte ratio,PLR)对胃癌患者生存预后的预测价值。方法分析132例原发性胃癌患者及30例健康对照的临床资料,采用Kaplan-Meier、Log-rank检验、多元COX回归分析胃癌患者的生存状况。结果病例组NLR、PLR水平均明显高于健康对照组(t=6.67,P=0.000;t=13.23,P=0.000);年龄越高、肿瘤直径越大、临床分期越高、分化程度越差、出现淋巴结转移及未进行手术治疗NLR、PLR有升高的趋势(P<0.05);NLR与PLR呈明显的正相关关系(r=0.3164,P=0.0002);低NLR组生存时间为(57.59±2.23)月(中位生存时间为55个月),高NLR组生存时间为(35.22±3.09)月(中位生存时间为37个月),2者差异有统计学意义(χ2=6.298,P=0.0361);低PLR组生存时间为(54.09±2.66)月(中位生存时间为54个月),高PLR组生存时间为(35.22±2.75)月(中位生存时间为37个月),2者差异有统计学意义(χ2=5.879,P=0.0377)。胃癌患者总体生存期的独立影响因素有年龄、临床分期、有无淋巴结转移及NLR、PLR水平(P<0.05)。结论胃癌患者NLR、PLR显著升高,与患者的年龄、肿瘤大小、转移程度、临床分期等密切相关,并且对于患者的生存预后变差具有一定的预测价值。

NLR和PLR与糖尿病肾脏病

目的:研究中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)与DKD患者主要实验室指标间的关系。方法:收集100例正常人和120例DKD患者的临床资料,将DKD患者根据e GFR分为早、中、晚期,NLR和PLR由全血细胞分析结果计算,进行统计分析。结果:(1)与健康人相比,NLR在DKD患者中明显升高(P=0.000),且随着疾病的进展而逐渐升高(P=0.000);(2)NLR与DKD患者的年龄、收缩压、平均动脉压、血肌酐、尿素氮、24-UTP、ESR和IL-6呈正相关(P<0.01),与血红蛋白、白蛋白和e GFR呈负相关(P<0.01);PLR与DKD患者的年龄呈正相关(P<0.05),与血红蛋白和白蛋白呈负相关(PHGB<0.05,PALB<0.01);(3)逐步回归结果显示,NLR与24-UTP间的关系为y=0.874+0.237x(y为24-UTP,x为NLR,P<0.01),NLR与e GFR间关系为y=89.912-7.622x(y为e GFR,x为NLR,P<0.01)。结论:NLR作为一个廉价、易测的指标可以很好地评估DKD患者的尿蛋白和肾功能水平。

治疗前PLR和NLR对鼻咽癌患者预后的影响

目的探讨鼻咽癌患者治疗前外周血中血小板与淋巴细胞比(platelet-lymphocyte ratio,PLR)、中性粒细胞与淋巴细胞比(neutrophil-lymphocyte ratio,NLR)与总生存期(overall survival,OS)、无进展生存期(progression-free survival,PFS)的相关性。方法回顾性分析西安交通大学第一附属医院和陕西省人民医院2009年1月至2013年9月期间初治的91例鼻咽癌患者临床资料,根据ROC曲线选取PLR和NLR的截断值,将患者根据截断值分组,采用Kaplan-Meier法和Log rank检验比较不同组患者的总生存率和无进展生存率,应用Cox比例风险模型进行单因素和多因素分析。结果当PLR=143.3、NLR=2.6时,对患者的预后预测价值最高。Cox多因素分析发现PLR≥143.3(RR=2.491,95%CI=1.139~5.451,P=0.022)、NLR≥2.6(RR=2.186,95%CI=1.021~4.682,P=0.044)时,患者的OS较短,而PLR≥143.3(RR=2.461,95%CI=1.242~4.874,P=0.01)时,患者的PFS较差。结论治疗前PLR和NLR可能是影响鼻咽癌患者预后的独立危险因素。

外周血炎症指标对晚期非小细胞肺癌免疫治疗疗效的预测价值

目的探讨外周血炎症指标对晚期非小细胞肺癌(NSCLC)免疫治疗疗效和预后的预测价值。方法回顾性分析2020年1月至2022年6月接受免疫治疗的晚期NSCLC患者107例,收集患者免疫治疗前的中性粒细胞和淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR),根据ROC曲线确定NLR和PLR的最佳临界值,分析NLR和PLR对晚期NSCLC患者免疫治疗近期疗效和远期疗效的影响。结果ROC曲线分析显示NLR最佳截断值为3.825,PLR最佳截断值为179;近期疗效分析表明高NLR水平组患者DCR显著低于低NLR水平组(54.3%vs 83.3%,P=0.001),高PLR水平组患者DCR亦显著低于低PLR水平组(59.0%vs 82.4%,P=0.008),但2组患者ORR差异无统计学意义(P>0.05)。Kaplan-Meier生存分析显示,低NLR水平组患者中位PFS高于高NLR水平组(11.0个月vs 6.0个月,P=0.014),低PLR水平组患者中位PFS高于高PLR水平组(11.0个月vs 6.0个月,P=0.034);低NLR水平组患者中位OS高于低NLR水平组(11.0个月vs 8.0个月,P=0.032),低PLR水平组患者中位OS高于高PLR水平组(12.0个月vs 11.0个月,P=0.045)。结论晚期NSCLC免疫治疗中,低基线水平NLR和PLR对患者免疫治疗的疗效和预后呈正相关,是预测晚期NSCLC患者免疫治疗的重要标志物。

术前NLR和PLR对上皮性卵巢癌患者预后的评估价值

目的:探讨术前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)对上皮性卵巢癌患者预后的评估价值。方法:收集2005年11月至2012年12月在天津市中心妇产科医院初治且经手术治疗的153例卵巢良性肿瘤和206例上皮性卵巢癌患者的临床病理资料,比较术前NLR和PLR在卵巢良恶性肿瘤的区别,根据统计学方法选取NLR和PLR临界值,分析NLR和PLR与上皮性卵巢癌临床病理因素的关系。通过单因素及多因素分析评估术前NLR和PLR对患者术后生存的影响。结果:术前NLR和PLR水平在上皮性卵巢癌中明显高于卵巢良性肿瘤。选取NLR=2.62和PLR=173分别作为临界值。单因素分析结果显示,FIGO分期晚、中-低分化、腹水、脉管癌栓、CA125≥35、NLR≥2.62、PLR≥173是影响患者术后无病生存期(DFS)的危险因素(P<0.05);FIGO分期晚、腹水、脉管癌栓、CA125≥35、PLR≥173是影响患者术后总生存期(OS)的危险因素(P<0.05)。多因素分析显示,FIGO分期晚、NLR≥2.62、脉管癌栓是上皮性卵巢癌患者DFS的独立危险因素(P<0.05)。结论:NLR和PLR方便测得且价格便宜,对卵巢癌的预后有一定的评估价值。

外周血NLR联合PLR对主动脉夹层的诊断意义

目的探讨外周血中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)对主动脉夹层(AD)患者的诊断意义。方法明确诊断的AD患者病例34例(AD组)、急性ST段抬高型心肌梗死病例48例(STEMI组)和低危胸痛病例50例(低危胸痛组),收集3组患者基础疾病等资料、记录入院时首次血常规检测的中性粒细胞计数(NEUT)、淋巴细胞计数(LYM)、血小板计数(PLT)等数据,计算NLR及PLR,应用受试者工作(ROC)曲线评估NLR和PLR对AD的诊断作用。结果AD组和STEMI组NEUT和NLR明显高于低危胸痛组(P<0.001),AD组PLT和PLR明显低于STEMI组(P分别为<0.001、0.006);AD组PLT明显低于低危胸痛组(P<0.001),且PLR亦有下降趋势(P=0.07);STEMI组与低危胸痛组PLT和PLR比较,差异无统计学意义(P分别为0.402、0.233);PLR诊断AD的能力曲线下面积(AUC)为0.655(P=0.008),NLR筛查STEMI和AD等高危胸痛的能力AUC为0.778(P<0.001),PLR对NLR筛选出的高危胸痛病例中AD的诊断能力AUC为0.683(P=0.006),应用NLR联合PLR的方法较单用PLR诊断AD的特异性有明显提高(χ^(2)=12.027,P=0.001)。结论NLR联合PLR的方法可用于AD的诊断,并有较高的特异性。

治疗前NLR和PLR对宫颈鳞癌患者预后的影响

目的探讨经手术治疗的宫颈鳞癌患者治疗前中性粒细胞与淋巴细胞比(neutrophil-tolymphocyte ratio,NLR)及血小板与淋巴细胞比(platelet-to-lymphocyteratio,PLR)与总生存期(overall survival,OS)、无病生存期(disease-free survival,DFS)和各临床病理因素的相关性。方法回顾性分析中山大学附属第一医院于2005年1月1日至2009年12月31日期间初治的并且经过手术治疗的143例宫颈鳞癌患者的临床病理资料,根据统计学方法选取NLR和PLR截断值,将患者根据截断值分组,分析NLR和PLR与患者生存、复发情况的相关性以及与临床病理因素的相关性。结果选取NLR=2.8和PLR=125分别作为截断值,高NLR组5年生存率为30.3%,低NLR组5年生存率为80%,差异有统计学意义(P=0.000)。高NLR组复发率为69.7%,低NLR组复发率为24.5%,差异有统计学意义(P=0.000)。高PLR组5年生存率为53.7%,低PLR组5年生存率为81.6%,差异有统计学意义(P=0.000)。高PLR组复发率为50%,低PLR组复发率为22.4%,差异有统计学意义(P=0.000)。经过单因素和多因素分析,国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)分期、术前化疗、病灶大小、外周血血小板计数(platelet,PLT),NLR值和PLR值是影响宫颈鳞癌患者总生存率和无病生存率的独立危险因素。结论治疗前NLR及PLR均是影响宫颈鳞癌患者总生存时间和无病生存时间的独立危险因素。

儿童化脓性关节炎感染后脓毒症继发急性肾损伤的早期预测

目的 探讨血小板/淋巴细胞比值(PLR)、高密度脂蛋白胆固醇(HDL-C)对儿童化脓性关节炎感染后脓毒症继发急性肾损伤(AKI)的早期预测价值。方法 以2018年6月至2023年10月河北省儿童医院骨科收治的173例化脓性关节炎感染后脓毒症患儿为研究对象,依据是否继发AKI分为非AKI组(105例)和AKI组(68例),记录所有患儿入院时基本资料,收集实验室指标包括血常规、C-反应蛋白(CRP)、降钙素原(PCT)、血肌酐(SCr)、HDL-C及入院时儿童序贯器官衰竭评分(pSOFA),并将上述数据进行统计分析;应用Logistic回归分析筛选继发AKI的独立危险因素,并以此为基础构建联合预测模型,通过受试者工作特征(ROC)曲线分析评估模型的预测价值。应用Hosmer-Lemeshow拟合优度检验、Booststrap重抽样法对预测模型的准确性进行内部验证,绘制临床决策曲线分析(DCA)评估预测模型的临床实用性。结果 (1)AKI组与非AKI组PCT、PLR、HDL-C及pSOFA评分比较差异有统计学意义(P<0.05);(2)Logistic回归分析显示,PLR、HDL-C是继发AKI的独立危险因素(P<0.05);(3)ROC曲线分析显示,PLR、HDL-C预测的曲线下面积(AUC)0.775和0.851,95%CI 0.720~0.829和0.803~0.899;两项指标联合预测AUC 0.912,95%CI 0.880~0.945;(4)两项联合预测校准后的预测结果与临床实际观察结果一致性较高,其预测效能曲线与临床实际发生的曲线具有良好的一致性;(5)临床DCA显示,阈概率为28%~80%时,可预测化脓性关节炎感染后脓毒症患儿早期继发AKI。结论 PLR、HDL-C是继发AKI的独立危险因素,两项联合检测诊断价值更高,可用于评估儿童化脓性关节炎感染后脓毒症早期继发AKI的风险。

术前外周血小板/淋巴细胞比值与胃癌初治患者临床病理特征及预后的相关性分析

目的探讨胃癌初治患者术前外周血小板/淋巴细胞比值(platelet-lymphocyte ratio,PLR)与患者临床病理特征之间的关系,并分析对患者预后的影响。方法选择2018年1月—2019年1月在龙岩市第一医院胃肠外科科确诊并收治的285例胃癌患者,以PLR=150为基线,共有193例低PLR患者(PLR<150,设置为低PLR组),92例高PLR患者(PLR≥150,设置为高PLR组)。分别比较高低PLR组患者的各类临床病理资料以及手术后1、3、5年总生存率(overall survival,OS)和无病生存率(diseasefreesurvival,DFS),以Cox风险回归模型评估影响胃癌预后因素。结果高PLR组肿瘤浸润程度深、淋巴结转移数多、TNM分期较晚、白蛋白较低,与低PLR组相比,差异有统计学意义(P<0.05);高低PLR组1、3、5年OS及DFS对比,差异有统计学意义(P<0.05)。结论术前PLR是影响胃癌患者DFS的独立预后因素,可以为临床治疗过程中提供依据。

Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases

The albumin-bilirubin(ALBI)score is a useful prognostic marker that predicts mortality in patients suffering from terminal diseases.Recently,it has been reported that ALBI score is a predictor of non-malignant liver diseases.The cutoff point of the ALBI score that distinguishes hepatocellular carcinoma from non-malignant liver disease is still not identified.Therefore,the ALBI score is a sensi-tive rather than a specific predictor of the poor outcomes of liver diseases.There are many hematological indices and ratios that are utilized as prognostic biomarkers.Among these biomarkers are the neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio(PLR),and platelet-hemoglobin ratio(PHR),which are useful discriminating prognostic biomarkers for liver diseases,e.g.,hepato-cellular carcinoma,hepatitis,liver fibrosis,etc.There is evidence that PLR and PHR are prognostic biomarkers that predict the poor outcomes of diseases.Therefore,concomitant measurements of ALBI score and PHR or ALBI score and PLR will improve the predictive value that can differentiate hepatocellular carcinoma from non-malignant diseases.